Research Topics
| A WimoSummaryAffiliation: Karolinska Institutet Country: Sweden Publications
| Collaborators
|
Detail Information
Publications
Time spent on informal and formal care giving for persons with dementia in SwedenAnders Wimo
HC Bergsjö, Box 16, S 820 70 Bergsjö, Sweden
Health Policy 61:255-68. 2002..Some carers do carry a very heavy 24 h responsibility. This aspect of caring must be addressed by the development of well-targeted respite and relief support programmes...
Validity and reliability of assessments of time. Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrumentAnders Wimo
Aging Research Center ARC, Division of Geriatric Epidemiology and Medicine, Neurotec, Karolinska Institutet, Huddinge Hospital, B84, S 141 86 Stockholm, Sweden
Arch Gerontol Geriatr 44:71-81. 2007..9). There was a high correlation between interview-based data and register data regarding hospital care, family physician, and district nurse visits. In conclusion, interviews may serve as a valid and reliable substitute for observations...
The magnitude of dementia occurrence in the worldAnders Wimo
Aging Research Center, Karolinska Institutet, Stockholm, Sweden
Alzheimer Dis Assoc Disord 17:63-7. 2003..In conclusion, the majority of demented elders live in less developed regions, and this proportion will increase considerably in the future...
An estimate of the worldwide prevalence and direct costs of dementia in 2003A Wimo
Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden
Dement Geriatr Cogn Disord 21:175-81. 2006..Although there are several sources of uncertainty, it is obvious that the worldwide costs are substantial and the expected increase in elderly people in the developing countries presents a great challenge...
Impact of donepezil treatment for Alzheimer's disease on caregiver timeAnders Wimo
Karolinska Institutet, Huddinge, Sweden
Curr Med Res Opin 20:1221-5. 2004..To assess the impact of donepezil treatment compared with placebo on caregiver time spent assisting patients with Alzheimer's disease (AD)...
Societal burden and economics of vascular dementia: preliminary results from a Swedish-population-based studyAnders Wimo
Neurotec, Division of Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
Int Psychogeriatr 15:251-6. 2003..The cost from a societal perspective was 23% higher for patients with VaD compared with patients with Alzheimer's disease ( p = .02)...
Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerationsAnders Wimo
Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden
Drugs Aging 21:279-95. 2004....
Economic aspects on drug therapy of dementiaA Wimo
Department of Neurotec, Aging Research Center, Karolinska Institute, Stockholm, Sweden
Curr Pharm Des 10:295-301. 2004..Available data show that there is support for a view that treatment is cost-neutral or perhaps cost saving which in combination with positive effects in terms of efficacy may indicate cost-effectiveness...
An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trialAnders Wimo
Department of Family Medicine, Umea University, Umea, Sweden
Dement Geriatr Cogn Disord 15:44-54. 2003....
[Can the costs of future needs of health and social services for the elderly be calculated?]A Wimo
Institutionen för folkhälsa och klinisk medicin, enheten för allmänmedicin, Umea Universitet
Lakartidningen 98:4042-8. 2001..Informal care of demented persons is about 4-5 times more extensive than formal care. There is a strong correlation between GNP per citizen and resources spent on health care...
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate ADB Winblad
Karolinska Institutet, Alzheimer s Disease Research Center, Division of Geriatric Medicine, Huddinge Hospital B, Stockholm, Sweden
Neurology 57:489-95. 2001..To evaluate the long-term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD...
Incremental patterns in the amount of informal and formal care among non-demented and demented elderly persons: results from a 3-year follow-up population-based studyA Wimo
Alzheimer Disease Research Center KI ADRC, Karolinska Institutet, Stockholm, Sweden
Int J Geriatr Psychiatry 26:56-64. 2011....
IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's DiseaseA Gustavsson
KI Alzheimer s Disease Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Novum Plan 5, 141 86 Stockholm, Sweden
J Nutr Health Aging 14:358-60. 2010....
3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapyB Winblad
Karolinska University Hospital Huddinge, Stockholm, Sweden
Dement Geriatr Cogn Disord 21:353-63. 2006..These data support the long-term efficacy and safety of donepezil...
The amount of informal and formal care among non-demented and demented elderly persons-results from a Swedish population-based studyG Nordberg
Aging Research Center ARC, Box 6401, 113 82 Stockholm, Sweden
Int J Geriatr Psychiatry 20:862-71. 2005..Knowledge regarding the amount of formal and informal care and its interaction at population-based level is limited...
Assessing the societal impact of acetylcholinesterase inhibitor therapiesB Winblad
Department of Clinical Neuroscience, Occupational Therapy and Elderly Care, Karolinska Institute, Stockholm, Sweden
Alzheimer Dis Assoc Disord 13:S9-19. 1999..Thus, the health economics of dementia is an extremely complex area of study that is rapidly growing, due to the likelihood that cost-effectiveness will form the basis for future reimbursement decisions...
Cost of illness due to dementia in SwedenA Wimo
Department of Geriatric Medicine, Karolinska Institute, Stockholm, Sweden
Int J Geriatr Psychiatry 12:857-61. 1997..The gross cost of illness due to dementia was estimated to be SEK30.7 billion in 1991 while the net cost was estimated to be SEK20 billion. The sensitivity analysis showed a variation between SEK20 billion and SEK36 billion in 1991...
The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementiaA Wimo
KI Alzheimer s Disease Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
J Nutr Health Aging 14:685-90. 2010..Thus it is fundamental that assessments of informal care are valid. Thus the aim was to analyse the validity of time estimates with the Resource Utilization in Dementia (RUD) instrument...
The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode projectA Wimo
Alzheimeŕs Disease Research Center, NCS, Karolinska Institute, Stockholm, Sweden
Int J Geriatr Psychiatry 26:825-32. 2011..Eurocode was administered by Alzheimer Europe. The aim was to describe the economic impact of dementia in Europe in 2008...
Underweight, weight loss and related risk factors among older adults in sheltered housing--a Swedish follow-up studyA G Mamhidir
Division of Gerontological Caring Science, Neurotec Department, Karolenska Institetutet, Stockholm, Sweden
J Nutr Health Aging 10:255-62. 2006..Underweight and weight loss are important factors in detecting malnutrition...
Cost analysis of incisional hernia repair by suture or meshL A Israelsson
Department of Surgery and Perioperative Science, Umea University, Umea, Sweden
Hernia 7:114-7. 2003..For retired patients, the total costs with a mesh repair were 1,898 SEK lower than with a suture repair. We conclude that in this setting, mesh repair of incisional hernias produced lower costs than suture repair...
Costs explained by function rather than diagnosis-results from the SNAC Nordanstig elderly cohort in SwedenC Lindholm
Department of Health Economics, Stockholm School of Economics, Stockholm, Sweden OptumInsight, Stockholm, Sweden
Int J Geriatr Psychiatry 28:454-62. 2013..Because the prevalence of many brain disorders rises with age, and brain disorders are costly, the economic burden of brain disorders will increase markedly during the next decades...
Outcome measures in Alzheimer's disease: do they go far enough?B Winblad
Karolinska Institutet, Alzheimer Research Center, Department of Clinical Neuroscience, Huddinge University Hospital, Sweden
Dement Geriatr Cogn Disord 11:3-10. 2000....
Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project--a population based study in SwedenGunilla Nordberg
Aging Research Center ARC, Karolinska Institutet, Stockholm, Sweden
Int J Geriatr Psychiatry 22:639-48. 2007..The aging of the population has become a worldwide phenomenon. This leads to increased demand for services and with limited resources it is important to find a way to estimate how resources can be match to those with greatest need...
Clinical and economic outcomes--friend or foe?Anders Wimo
Department of Neurobiology, Care and Society, Karolinska University Hospital, Stockholm, Sweden
Int Psychogeriatr 19:497-507. 2007..Both dementia-specific and generic quality of life instruments are required. Models are necessary but must be transparent so that the assumptions on which the models are built can be critically analyzed...
Health utilities in mild cognitive impairment and dementia: a population study in SwedenMattias Ekman
Stockholm Health Economics, Stockholm, Sweden
Int J Geriatr Psychiatry 22:649-55. 2007..To collect new primary data on community-based health utilities (time trade-off values) in different stages of mild cognitive impairment and dementia from a general population sample...
Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's diseaseBengt Winblad
Karolinska Institutet Alzheimer Research Center, Huddinge, Sweden
Int J Geriatr Psychiatry 22:485-91. 2007..Transdermal patches may offer advantages over conventional oral formulations...
Cost-effectiveness of a multidisciplinary intervention model for community-dwelling frail older peopleRené J F Melis
Radboud University Nijmegen Medical Centre, Department of Geriatric Medicine, Nijmegen, The Netherlands
J Gerontol A Biol Sci Med Sci 63:275-82. 2008..This article reports about the cost-effectiveness of the Dutch Geriatric Intervention Program (DGIP) compared to usual care in frail older people at 6-month follow-up from a health care system's point of view...
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factorsRaj N Kalaria
Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, UK
Lancet Neurol 7:812-26. 2008..Dementia costs in developing countries are estimated to be US$73 billion yearly, but care demands social protection, which seems scarce in these regions...
More illness and less disease? A 20-year perspective on chronic disease and medicationBertil Hagstrom
Department of Primary Health Care, Goteborg University, Goteborg, Sweden
Scand J Public Health 34:584-8. 2006..Aims: To investigate the apprehension in respect of chronic disease among the working population in a Swedish community in 2000 compared with 1980...
The use of angiotensin-converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very oldInga Klarin
Aging Research Center, Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Gavlegatan 16, 113 30, Stockholm, Sweden
Eur J Clin Pharmacol 62:555-62. 2006..The aim of this study was to investigate drug treatment patterns for heart failure (HF) in the very elderly and, in particular, to determine if angiotensin-converting enzyme inhibitors (ACEIs) were under-used by demented persons...
Pharmacoeconomics of mild cognitive impairmentAnders Wimo
Division of Geriatric Medicine, Neurotec, Karolinska Institutet, Stockholm, Sweden
Acta Neurol Scand Suppl 179:94-9. 2003..From the Kungsholmen project in Sweden, there are indications that the postponement between MCI and manifest dementia may result in short-term benefits (a few years) of about SEK50,000 (5300 US dollars)...
Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's diseaseAnders Wimo
Division of Geriatric Epidemiology Sector of Health Economy, Neurotec, Karolinska Institute, Huddinge, Sweden
Pharmacoeconomics 21:327-40. 2003..Alzheimer's disease (AD) is a devastating illness that causes enormous emotional stress to affected families and is associated with substantial medical and nonmedical costs...
A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohortInga Klarin
Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Sweden
Pharmacoepidemiol Drug Saf 12:669-78. 2003..To describe drug use among the elderly, with focus on cardiovascular drugs and regional differences...
A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC)Marten Lagergren
Stockholm Gerontology Research Center, Stockholm, Sweden
Aging Clin Exp Res 16:158-68. 2004..A large, national, long-term, longitudinal, multi-purpose study has been launched in Sweden--the Swedish National study on Aging and Care (SNAC). The study involves four research centers collecting data in four different areas of Sweden...
The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very oldInga Klarin
Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden
Drugs Aging 22:69-82. 2005..The aim of this study was to explore possible associations of IDU with acute hospitalisation and mortality in an elderly population during 3 years of follow-up...
Determinants of costs of care for patients with Alzheimer's diseaseLinus Jönsson
Division of Geriatric Epidemiology, The Neurotec Department, Karolinska Institutet, Stockholm, Sweden
Int J Geriatr Psychiatry 21:449-59. 2006..Alzheimer's disease (AD), the most common cause of dementia, is a major cause of disability and care burden in the elderly. This study aims to estimate the costs of formal and informal care and identity determinants of care costs...
Patient- and proxy-reported utility in Alzheimer disease using the EuroQoLLinus Jönsson
Neurotec, Section for Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
Alzheimer Dis Assoc Disord 20:49-55. 2006..The study shows that the EuroQoL can be used to rate utilities in Alzheimer disease, but there are important differences between patient- and proxy-ratings...
Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in SwedenFrances B Garfield
Caro Research Institute, Concord, Massachusetts 01742, USA
Pharmacoeconomics 20:629-37. 2002..Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective in managing patients with Alzheimer's disease in clinical trials...
[There is a need to reform dementia care. Resources are not used optimally--time for evidence-based care]Jan Marcusson
Geriatriska kliniken,
Lakartidningen 103:1022-4, 1027-8. 2006
Older patients awaiting emergency department treatmentAnnica Larsson Kihlgren
Centre for Nursing Science, Orebro University Hospital, Orebro, Sweden
Scand J Caring Sci 18:169-76. 2004..The way, in which nursing care was carried out, which in this context is discussed in terms of praxis and poieses, appeared to be of major importance for the older peoples' experiences when visiting the ED...
